The genomics company said the organizational change will eventually reduce annual payroll and benefit expenses by $12.8 million, per the June 9 filing. The reduction plan is expected to be completed by the first quarter of fiscal 2024, which ends March 31. 23andMe’s net losses increased from $217 million to $317 million in the 12 months ending in March, according to a May earnings report.
“As we continue to navigate uncertainties in the global economy and financial markets, we made the difficult decision to reduce our workforce by 9 percent,” a company spokesperson emailed Becker’s. “We believe this will help ensure 23andMe is set up for long-term growth and success. Those impacted have been notified, and we are truly grateful for their part in helping grow our business and delivering on our mission.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.